ESC 2018 In this debate, the different viewpoints supporting the European and American Guidelines on Hypertension were fiercely defended, although overlap prevails.
ESC 2018 Key messages of the 2018 ESC/ESH Guidelines for hypertension include no change in the definition of hypertension, treatment for those with high-normal BP and grade I hypertension and initiation of two-drug combination.
This is a summary of presentation given by prof. Grobbee, in which he discusses how to reduce CV risk in patients with T2DM, considering the effects of glucose control and the effect of newer agents.
Black individuals have a significantly higher risk for hypertension compared with whites, from young adulthood through middle age, irrespective of BP before the age of 30 years.
BP responses to exercise are similar in treated–controlled, treated-uncontrolled, and untreated hypertensives but higher compared with normotensives.
Individuals with hypertension at mid-life, defined as SBP ≥130 mmHg at the age of 50, have an increased risk of dementia, which is proportional to the duration of the exposure to hypertension
Clinical updates in management of cardiovascular risk Hypertension is one of the most established and major risk factors for CVD. Prof Hobbs gives an overview on the impact of hypertension on CV outcomes, how the diagnosis is made, on the benefits of therapy, and what the BP targets are.
Prof. Hobbs stresses the importance of CVRM in primary care and how to manage this risk beyond glucose control.
Before publication later this year, a first look at the new 2018 ESC/ESH Guidelines of hypertension was presented. One of the key messages was the unchanged definition of hypertension of BP >140/90 mmHg.
CV risk is high in obese women without metabolic abnormalities, as well as in women with hypertension, diabetes or hypercholesterolemia, independently of their body mass index.
Hypertensive patients treated with renal denervation in the presence of antihypertensive drugs had reduced BP levels compared to sham controls in the SPYRAL HTN-ON MED trial.
VBWG at ACC 2018 After lack of sham-controlled trials, the SPYRAL program has started to test the efficacy of renal denervation in patients with uncontrolled hypertension. Two pilot studies with a sham controlled group in patients without and with medications are nearly finished.